Cipher Pharmaceuticals (CPH) Stock Price, News & Analysis

Company Overview

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.

Key Stats

• Today's Range: C$16.84 to C$17.31
• 50-Day Range: C$14.42 to C$19.74
• 52-Week Range: C$11.87 to C$20.56
• Volume: 43,906 shs
• Average Volume: 31,285 shs
• Market Capitalization: C$431.14 million
• P/E Ratio: 14.27
• Dividend Yield: N/A
• Price Target: C$17.00
• Consensus Rating: Hold

Cipher Pharmaceuticals Stock Analysis - MarketRank™

Cipher Pharmaceuticals scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Cipher Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Upside/Downside

The consensus price target for Cipher Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Cipher Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cipher Pharmaceuticals is 14.27, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.39.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cipher Pharmaceuticals is 14.27, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.78.

Price to Book Value per Share Ratio

Cipher Pharmaceuticals has a P/B Ratio of 3.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CPH.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cipher Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Cipher Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Sentiment

Cipher Pharmaceuticals has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cipher Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

42.00% of the stock of Cipher Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

2.27% of the stock of Cipher Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 5/20/2026

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:CPH
• Previous Symbol: TSE:DND
• CIK: N/A
• Web: www.cipherpharma.com
• Phone: +1-905-6025840
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cipher Pharmaceuticals: C$17.00
• High Price Target: C$17.00
• Low Price Target: C$17.00
• Potential Upside/Downside: +0.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): C$1.19
• Trailing P/E Ratio: 14.27
• Forward P/E Ratio: 13.16
• P/E Growth: N/A
• Net Income: C$11.41 million
• Net Margins: 60.82%
• Pretax Margin: N/A
• Return on Equity: 25.69%
• Return on Assets: 7.90%

Debt

• Debt-to-Equity Ratio: 0.32
• Current Ratio: 1.25
• Quick Ratio: 2.67

Sales & Book Value

• Annual Sales: C$50.94 million
• Price / Sales: 8.46
• Cash Flow: C$4.81 per share
• Price / Cash Flow: 3.53
• Book Value: C$5.25 per share
• Price / Book: 3.23

Miscellaneous

• Outstanding Shares: 25,391,000
• Free Float: N/A
• Market Cap: C$431.14 million
• Optionable: Not Optionable
• Beta: 0.89